Yıl: 2019 Cilt: 3 Sayı: 2 Sayfa Aralığı: 112 - 115 Metin Dili: İngilizce DOI: 10.14744/ejmo.2019.31913 İndeks Tarihi: 22-04-2020

Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer

Öz:
Objectives: Lung cancer accounts for 20% of cancer-related deaths worldwide. Several studies have shown that Vitamin D levels at the time of diagnosis are prognostic in lung cancer. In this study, we evaluated the relationship betweenpre-diagnosis Vitamin D replacement levels and platinum-based chemotherapy results.Methods: In this cross-sectional study, we retrospectively analyzed archive records of all 247 patients diagnosed withlung cancer from an oncology center in Turkey, between 2012-2018. The chemotherapy outcomes, Vitamin D levels andreplacement doses of these patients up to 6 months ago were recorded.Results: Vitamin D levels of 153 patients were below 15 ng/mL, 65 patients had a level of 15-30 ng/mL, and 29 patientshad a vitamin D level higher than 30 ng/mL. In the study population, 215 had a replacement below 300.000 IU whereas32 had a replacement above 300.000 IU. When the patients were evaluated based on their chemotherapy responses, nodifference was observed between the patients with below and above 300.000 IU. In our study, Vitamin D and replacement level at the time of diagnosis did not change the chemotherapy response.Conclusion: Vitamin D replacement levels were not significantly associated with chemotherapy outcomes in our study.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
  • 2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977–1010.
  • 3. Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med 2011;2:181–193.
  • 4. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26–34.
  • 5. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
  • 6. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, et al. Vitamin D is associated with improved survival in early-stage nonsmall cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:2303–9.
  • 7. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468–83.
  • 8. Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int 2009;104:909–14.
  • 9. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem 2015;36:299–305.
  • 10. Chen GC, Zhang ZL, Wan Z, Wang L, Weber P, Eggersdorfer M, et al. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer Causes Control 2015;26:1719–28.
  • 11. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007;25:479–85.
  • 12. Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010;116:3294–303.
  • 13. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:2239–45.
  • 14. Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol 2011;123:30–6.
  • 15. Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-smallcell lung cancer. Clin Lung Cancer 2013;14:433–9.
  • 16. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009;29:3511–36.
  • 17. Akiba T, Morikawa T, Odaka M, Nakada T, Kamiya N, Yamashita M, et al. Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Cancer Res 2018;24:4089–97.
  • 18. Ma K, Xu W, Wang C, Li B, Su K, Li W. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy. Cancer Biomark 2017;18:297–303.
  • 19. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5596–602.
  • 20. Anic GM, Weinstein SJ, Mondul AM, Männistö S, Albanes D. Serum vitamin D, vitamin D binding protein, and lung cancersurvival. Lung Cancer 2014;86:297–303.
APA araz m, Beypinar I, Beypınar D, demir h, Uysal M (2019). Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. , 112 - 115. 10.14744/ejmo.2019.31913
Chicago araz murat,Beypinar Ismail,Beypınar Dilek,demir hacer,Uysal Mukremin Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. (2019): 112 - 115. 10.14744/ejmo.2019.31913
MLA araz murat,Beypinar Ismail,Beypınar Dilek,demir hacer,Uysal Mukremin Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. , 2019, ss.112 - 115. 10.14744/ejmo.2019.31913
AMA araz m,Beypinar I,Beypınar D,demir h,Uysal M Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. . 2019; 112 - 115. 10.14744/ejmo.2019.31913
Vancouver araz m,Beypinar I,Beypınar D,demir h,Uysal M Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. . 2019; 112 - 115. 10.14744/ejmo.2019.31913
IEEE araz m,Beypinar I,Beypınar D,demir h,Uysal M "Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer." , ss.112 - 115, 2019. 10.14744/ejmo.2019.31913
ISNAD araz, murat vd. "Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer". (2019), 112-115. https://doi.org/10.14744/ejmo.2019.31913
APA araz m, Beypinar I, Beypınar D, demir h, Uysal M (2019). Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. Eurasian Journal of Medicine and Oncology, 3(2), 112 - 115. 10.14744/ejmo.2019.31913
Chicago araz murat,Beypinar Ismail,Beypınar Dilek,demir hacer,Uysal Mukremin Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. Eurasian Journal of Medicine and Oncology 3, no.2 (2019): 112 - 115. 10.14744/ejmo.2019.31913
MLA araz murat,Beypinar Ismail,Beypınar Dilek,demir hacer,Uysal Mukremin Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. Eurasian Journal of Medicine and Oncology, vol.3, no.2, 2019, ss.112 - 115. 10.14744/ejmo.2019.31913
AMA araz m,Beypinar I,Beypınar D,demir h,Uysal M Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 112 - 115. 10.14744/ejmo.2019.31913
Vancouver araz m,Beypinar I,Beypınar D,demir h,Uysal M Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 112 - 115. 10.14744/ejmo.2019.31913
IEEE araz m,Beypinar I,Beypınar D,demir h,Uysal M "Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer." Eurasian Journal of Medicine and Oncology, 3, ss.112 - 115, 2019. 10.14744/ejmo.2019.31913
ISNAD araz, murat vd. "Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer". Eurasian Journal of Medicine and Oncology 3/2 (2019), 112-115. https://doi.org/10.14744/ejmo.2019.31913